AG

Anta Gkelou

Partner at Sofinnova Partners

Paris, Île-de-France

Investor
VC

Invests in

Sectors:

BioTech

Locations:

Paris, France

  • Min Investment:

    $100,000.00

  • Max Investment:

    $5,000,000.00

  • Target Investment:

    $1,500,000.00

Skills

Communication and Presentation Skills
Public Speaking
Time Management
Budget Management
Result oriented problem solving skills
Life Sciences
Conference Speaking
Scientific Analysis
Teamwork
Resource Management
project management
Team Coordination
International Networking
Strategic Roadmaps
Project planning according to timelines and deadlines
Ability to work independently
Generation of innovative ideas
Applied Writing Skills
Chronic Obstructive pulmonary disease
Cardiovascular Biology

Education

Work Experience

Sofinnova Partners

2017

  • Partner

    2024

  • Principal

    2020 - 2024

  • Associate

    2017 - 2020

Noema Pharma

2020

  • Board Observer

    2020

France Invest

2021 - 2024

  • Member Board Of Directors -35

    2021 - 2024

Enthera Pharmaceuticals

2020 - 2024

  • Board Observer

    2020 - 2024

Nitrase Therapeutics

2020 - 2024

  • Board Observer

    2020 - 2024

Clinical Affairs, Life Sciences, Danone Nutricia Research

2016 - 2017

  • Immunology Scientist

    2016 - 2017

Institute of blood and vessels

2015 - 2016

  • Postdoctoral Fellow

    2015 - 2016

    Vascularisation in Alzheimer's disease

Inserm

2013 - 2016

  • Postdoctoral Fellow

    2013 - 2016

    Paris centre of cardiovascular research, PARCC- INSERM U970 Key areas of research: Immunology: The role of mast cells in cardiac function following myocardial infartcion; The role of CXCL12/CXCR4 interactions in regulating cardiac remodeling following myocardial infarction, under the supervision of Dr. Jean-Sebastien Silvestre

National Heart and Lung Institute, Imperial College London, Pfizer

2008 - 2012

  • Clinical Medical research, CASE studentship with Pfizer

    2008 - 2012